文献速递胸部肿瘤

循环肿瘤细胞检测ALK重排用于晚期NSCLC无创纵向管理的前瞻性多中心验证

Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-02-03

该多中心前瞻性观察研究纳入203例IIIB/IV期NSCLC患者(81例ALK阳性、122例ALK阴性),评估循环肿瘤细胞(CTC)作为组织ALK分析替代标志物的价值。基线时CTC免疫细胞化学检测ALK重排与组织检测高度一致(敏感性94.4%、特异性89.4%),但FISH分析性能较低。CTC基线水平或动态变化与总生存或无进展生存无显著关联。

要点

  • CTC免疫细胞化学检测ALK重排与组织检测高度一致,可作为组织活检的补充工具。
  • CTC的FISH分析敏感性仅35.6%、特异性56.9%,性能低于免疫细胞化学。
  • ALK阳性患者中CTC基线水平或动态变化与OS或PFS无显著关联。

核心结论

  • CTC可作为组织活检的补充工具用于检测ALK重排。
  • CTC纵向分析有望用于该人群的实时监测和改善分子指导治疗。

研究设计与样本

  • 多中心、前瞻性观察研究(NCT02372448),纳入法国九家中心的203例IIIB/IV期NSCLC患者。
  • 81例经免疫组织化学或FISH检测为ALK阳性,122例经石蜡包埋组织标本检测为ALK阴性。
  • 在基线以及ALK抑制剂启动后6周和12周或疾病进展时采集血样。
  • 采用过滤法富集后,用免疫细胞化学和FISH分析CTC的ALK基因重排。

主要发现

  • 基线时组织与CTC免疫细胞化学检测ALK重排高度一致:敏感性94.4%,特异性89.4%。
  • FISH分析性能较低:敏感性35.6%,特异性56.9%。
  • ALK阳性NSCLC患者中,CTC基线水平或动态变化与总生存无显著关联(HR=0.59,95%CI:0.24-1.5,p=0.244)。
  • ALK阳性NSCLC患者中,CTC基线水平或动态变化与无进展生存无显著关联(HR=0.84,95%CI:0.44-1.6,p=0.591)。

临床怎么用

  • 在组织不足或无法获取组织时,可考虑用CTC免疫细胞化学检测ALK重排作为补充。
  • CTC FISH分析敏感性低,不宜单独用于ALK重排检测。
  • CTC纵向分析可用于ALK阳性NSCLC患者的实时监测,但需进一步验证其临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with advanced-stage NSCLC whose tumors harbor an ALK gene rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of tumor biopsy samples contain insufficient tissue for successful ALK molecular characterization. This study evaluated the added value of analyzing circulating tumor cells (CTCs) as a surrogate to ALK tissue analysis and as a function of the response to ALKi. METHODS: We conducted a multicenter, prospective observational study (NCT02372448) of 203 patients with stage IIIB/IV NSCLC across nine French centers, of whom 81 were ALK positive (immunohistochemistry or fluorescence in situ hybridization [FISH]) and 122 ALK negative on paraffin-embedded tissue specimens. Blood samples were collected at baseline and at 6 and 12 weeks after ALKi initiation or at disease progression. ALK gene rearrangement was evaluated with CTCs using immunocytochemistry and FISH analysis after enrichment using a filtration method. RESULTS: At baseline, there was a high concordance between the detection of an ALK rearrangement in the tumor tissue and in CTCs as determined by immunocytochemistry (sensitivity, 94.4%; specificity 89.4%). The performance was lower for the FISH analysis (sensitivity, 35.6%; specificity, 56.9%). No significant association between the baseline levels or the dynamic change of CTCs and overall survival (hazard ratio = 0.59, 95% confidence interval: 0.24-1.5, p = 0.244) or progression-free survival (hazard ratio = 0.84, 95% confidence interval: 0.44-1.6, p = 0.591) was observed in the patients with ALK-positive NSCLC. CONCLUSIONS: CTCs can be used as a complementary tool to a tissue biopsy for the detection of ALK rearrangements. Longitudinal analyses of CTCs revealed promise for real-time patient monitoring and improved delivery of molecularly guided therapy in this population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ilié M, Mazières J, Chamorey E, et al. Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC. J Thorac Oncol. 2021. PMID: 33545389. doi:10.1016/j.jtho.2021.01.1617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。